Amylin Competitive Intelligence: April 2026
Mar 1, 2026 – Apr 26, 2026
Five developments across the amylin receptor agonist landscape: petrelintide's Phase 2 ZUPREME-1 trial showing up to 10.7% weight loss with placebo-like GI tolerability; ABBV-295 Phase 1 MAD data confirming up to 9.79% weight reduction with no SAEs; a published in vitro characterization of cagrilintide's skeletal muscle mitochondrial profile; Structure Therapeutics announcing ACCG-2671 NHP combination data at ADA 2026; and the AbbVie/Gubra licensing deal that brought ABBV-295 to a large-cap commercial partner.
Read the full report
Enter your details below to access the complete analysis — clinical timelines, competitive landscape, and analyst commentary.
Want a report like this for your target?
We build custom intelligence reports scoped to your therapeutic area, asset, or investment thesis.
Book a Call